SHAREme.

Scientific Hub of Applied Research in Emerging Medical science & technology

Received: 11.10.2025 Revised: 22.11.2025 Accepted: 6.12.2025

check for updates

Review Article

REVOLUTIONIZING ONCOLOGY: RECENT ADVANCES IN IMMUNOTHERAPY AND IMMUNE CHECKPOINT INHIBITORS FOR CANCER TREATMENT

VEMU PRIYANKA

School of Pharmacy, Vels Institute of Science, Technology & Advanced Studies (VISTAS), Pallavaram, Chennai, 600 117, India.
Author Email: priyankavemu8@gmail.com

Abstract: Cancer immunotherapy has transformed the therapeutic landscape of oncology by harnessing the body's immune system to recognize and eradicate malignant cells. Over the past decade, immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR)-T cell therapies, and personalized neoantigen vaccines have redefined treatment paradigms across multiple malignancies. The discovery of key regulatory pathways such as programmed cell death protein-1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) has been instrumental in elucidating the mechanisms of immune tolerance and tumor immune evasion. The clinical success of monoclonal antibodies targeting these checkpoints such as pembrolizumab, nivolumab, and ipilimumab has led to durable responses in cancers once considered refractory to treatment. Recent innovations include the development of bispecific and trispecific antibodies, integration of CAR-T and CAR-NK cells for solid tumors, and multi-omics-guided precision immunotherapy. However, the rise in immune-related adverse events (irAEs), resistance mechanisms, and variability in patient response highlight the need for predictive biomarkers and personalized strategies. Emerging evidence suggests that the integration of artificial intelligence (AI), nanomedicine, and systems biology will optimize therapeutic efficacy and minimize toxicity. This review provides a comprehensive analysis of the mechanistic, translational, and clinical advances in cancer immunotherapy from 2019 to 2025, emphasizing novel strategies that are shaping the future of precision oncology.

Keywords: Immunotherapy, PD-1/PD-L1 inhibitors, CAR-T cells, immune checkpoints, tumor microenvironment

Correspondence should be addressed to
Vemu Priyanka; Email: *priyankavemu8@gmail.com*

1.0 Introduction

Immunotherapy represents a paradigm shift in oncology, transitioning from the traditional cytotoxic approaches of chemotherapy and radiotherapy to biologically precise interventions that modulate host immune responses. The concept that the immune system could recognize and eliminate malignant cells, once speculative, has

now been substantiated by clinical and molecular evidence. Pioneering discoveries in tumor immunology such as cancer immunoediting, neoantigen presentation, and checkpoint signaling have underpinned the development of immune-based therapeutics capable of inducing durable remission in patients with metastatic disease. The success of checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4 has validated the therapeutic potential of immune modulation and expanded the spectrum of treatable cancers, including melanoma, non-small cell lung carcinoma (NSCLC), renal cell carcinoma, and Hodgkin lymphoma [1]. Modern immunotherapy operates through several mechanistic avenues. The first involves the reinvigoration of exhausted T cells, a phenomenon commonly induced by chronic antigen exposure in the tumor microenvironment. Checkpoint inhibitors disrupt inhibitory signaling cascades that suppress T-cell function, restoring cytotoxic capacity and promoting sustained antitumor immunity. The second major strategy is the adoptive transfer of genetically modified lymphocytes, exemplified by CAR-T cell therapy, which enables patient-derived T cells to specifically target tumor-associated antigens with high affinity [2].

The evolution of immunotherapy has been accelerated by advancements in bioinformatics, molecular profiling, and high-throughput sequencing, allowing for deeper characterization of tumor antigens and immune signatures. In particular, the integration of single-cell RNA sequencing and T-cell receptor (TCR) repertoire analysis has elucidated the complex interplay between immune cells and cancer niches, guiding the rational design of immunotherapeutics [3]. Despite its transformative impact, immunotherapy remains limited by heterogeneous responses, immune escape, and the onset of irAEs. Therefore, ongoing research focuses on predictive biomarkers, novel checkpoint molecules, and combination regimens that can overcome resistance while maintaining safety [4]. The period between 2019 and 2025 has witnessed exponential growth in clinical immuno-oncology, with over 5,000 active trials globally evaluating combinations of ICIs with chemotherapy, targeted therapy, or radiotherapy. Collectively, these developments underscore a transition toward a systems-based approach, where immune modulation, molecular precision, and data-driven personalization converge to define the next generation of cancer therapeutics [5].

1.1 Mechanistic Basis of Immune Checkpoint Regulation

The immune system operates through a delicate balance between activation and tolerance. This equilibrium is maintained by co-stimulatory and co-inhibitory pathways, collectively known as immune checkpoints, which regulate T-cell activation to prevent autoimmunity. In the context of cancer, tumor cells exploit these inhibitory pathways to evade immune surveillance, primarily through overexpression of checkpoint ligands or modulation of antigen presentation machinery [6].

At the molecular level, immune checkpoints function as signal transduction hubs within the immunological synapse. When a T cell recognizes an antigen via its TCR, a secondary signal is required to confirm activation. The engagement of co-stimulatory molecules like CD28 with B7 ligands on antigen-presenting cells (APCs) triggers full activation. Conversely, checkpoint molecules such as PD-1 and CTLA-4 transmit inhibitory signals that attenuate this process, thereby reducing cytokine secretion, proliferation, and cytotoxic activity [7]. CTLA-4 primarily regulates the early stages of T-cell activation in lymphoid organs by outcompeting CD28 for binding to B7 molecules, effectively dampening the activation threshold. PD-1, in contrast, acts predominantly in peripheral tissues during the effector phase, interacting with its ligands PD-L1 and PD-L2 on tumor cells and immune cells to induce anergy or apoptosis of T cells [8]. Recent findings have expanded this landscape by identifying additional checkpoints such as lymphocyte-activation gene 3 (LAG-3), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), and T-cell immunoreceptor with Ig and ITIM domains (TIGIT), all of which contribute to immune exhaustion and tumor persistence [9].

Emerging evidence from structural biology and cryo-electron microscopy has elucidated the conformational changes induced by checkpoint receptor–ligand binding, offering mechanistic insight into antibody-based blockade. For instance, PD-1 binding to PD-L1 induces phosphorylation of immunoreceptor tyrosine-based inhibitory motifs (ITIMs), recruiting SHP-2 phosphatase that

dephosphorylates proximal TCR signaling molecules such as CD3ζ and ZAP70. Blocking PD-1–PD-L1 interaction restores phosphorylation cascades and reactivates effector functions [10]. In addition to T cells, other immune subsets such as regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs) contribute to checkpoint-mediated immunosuppression. This has spurred the development of multitargeted therapies that simultaneously inhibit multiple checkpoints or modulate the immunosuppressive milieu [11]. Understanding the spatiotemporal dynamics of these pathways remains essential for optimizing therapeutic regimens and predicting patient outcomes.

1.2 PD-1/PD-L1 Axis: Mechanisms and Therapeutic Antibodies

The PD-1/PD-L1 signaling axis represents one of the most extensively characterized immune checkpoints in oncology. Programmed death-1 (PD-1), expressed on activated T and B lymphocytes, interacts with PD-L1 and PD-L2 ligands expressed on tumor cells, APCs, and endothelial cells to attenuate immune activation. This interaction is a physiological mechanism to prevent tissue damage during inflammation; however, in malignancy, it becomes a potent tool for immune evasion [12]. Upon PD-1 engagement, downstream signaling pathways involving SHP-1/2 phosphatases are activated, leading to dephosphorylation of CD28 and PI3K components, which suppresses AKT/mTOR signaling and T-cell metabolism. This results in reduced proliferation, cytokine production, and survival of effector T cells. Tumors with high PD-L1 expression, such as NSCLC, melanoma, renal cell carcinoma, and urothelial carcinoma, show profound resistance to immune attack unless this axis is therapeutically blocked [13].

Monoclonal antibodies targeting PD-1 or PD-L1 have revolutionized clinical oncology. Pembrolizumab and nivolumab, the first PD-1 inhibitors approved, have demonstrated superior survival benefits compared to standard chemotherapy in several tumor types. Atezolizumab, durvalumab, and avelumab targeting PD-L1 offer similar efficacy with varying toxicity profiles. The pivotal KEYNOTE and CHECKMATE trials established the clinical relevance of PD-L1 expression as a predictive biomarker for therapy selection [14]. Recent research emphasizes the importance of tumor mutational burden (TMB), microsatellite instability (MSI), and neoantigen load as additional determinants of response to PD-1/PD-L1 blockade. Patients with high TMB or MSI-H tumors often exhibit higher immunogenicity, correlating with favorable outcomes [15]. Furthermore, combination therapies integrating PD-1 inhibitors with tyrosine kinase inhibitors (TKIs), anti-angiogenic agents, or radiation have produced synergistic effects by enhancing antigen presentation and reducing immune exclusion [16].

The next generation of PD-1/PD-L1 inhibitors includes small-molecule antagonists and bispecific antibodies designed to target PD-L1 concurrently with other immunosuppressive ligands such as TGF-β. Novel delivery systems employing nanoparticles and exosome-based carriers are being investigated to enhance tissue penetration and reduce systemic toxicity [17]. Collectively, the PD-1/PD-L1 pathway continues to serve as the cornerstone of immune checkpoint therapy, with ongoing innovations aiming to refine efficacy, expand indications, and personalize treatment strategies.

1.3 CTLA-4 Blockade: Synergistic and Combination Approaches

Cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) was the first immune checkpoint molecule to be targeted for cancer therapy, marking a milestone in the evolution of immuno-oncology. Functionally, CTLA-4 acts as an inhibitory receptor expressed on activated T cells and regulatory T cells, competing with CD28 for binding to B7 ligands on APCs. This competition reduces co-stimulatory signaling, suppressing T-cell activation and proliferation at the priming stage within lymphoid tissues [18]. The clinical breakthrough came with ipilimumab, a fully human monoclonal antibody against CTLA-4, which demonstrated durable survival benefits in metastatic melanoma and led to its FDA approval in 2011. Mechanistically, CTLA-4 blockade enhances the activation and expansion of tumor-specific effector T cells while depleting immunosuppressive Tregs through Fc-mediated cytotoxicity. The result is a

sustained antitumor immune response capable of mediating long-term remission in select patient populations [19].

Despite its efficacy, CTLA-4 inhibition is associated with higher incidence of irAEs compared to PD-1 blockade, attributed to its broad activation of the immune system. These toxicities, including colitis, dermatitis, and hepatitis, necessitate careful management using corticosteroids and immunomodulatory agents such as infliximab [20]. Combination therapy involving CTLA-4 and PD-1 inhibitors has emerged as a strategy to enhance response rates while maintaining tolerable safety profiles. The combination of nivolumab and ipilimumab, for instance, has shown superior efficacy in melanoma, renal cell carcinoma, and colorectal cancer with mismatch repair deficiency. Mechanistically, CTLA-4 blockade amplifies T-cell priming, while PD-1 inhibition sustains effector function within the tumor microenvironment, producing synergistic effects [21].

Recent advances include the design of next-generation CTLA-4 antibodies with modified Fc domains that preferentially deplete Tregs in tumors while sparing peripheral tissues. Novel bispecific antibodies simultaneously targeting CTLA-4 and PD-1 or other checkpoints are under evaluation in phase II and III trials. Additionally, localized delivery strategies, such as intratumoral injection of CTLA-4 inhibitors encapsulated in hydrogels or nanoparticles, are being explored to reduce systemic toxicity [22]. Together, CTLA-4 blockade continues to play a critical role in combination immunotherapy, serving as both a foundational mechanism for immune activation and a template for designing more selective and tolerable checkpoint inhibitors in future clinical applications.

1.4 CAR-T Cell Therapy: Engineering the Adaptive Immune System

Chimeric Antigen Receptor (CAR)-T cell therapy represents one of the most revolutionary breakthroughs in personalized cancer immunotherapy. Unlike checkpoint inhibitors that modulate endogenous immune responses, CAR-T cells are engineered ex vivo to recognize specific tumor antigens independently of the major histocompatibility complex (MHC), enabling robust cytotoxic responses even against immune-evasive malignancies [23]. The basic construct of a CAR molecule integrates an extracellular antigen-recognition domain derived from a monoclonal antibody's single-chain variable fragment (scFv), a transmembrane hinge region, and one or more intracellular signaling domains such as CD3ζ, CD28, or 4-1BB that activate downstream effector functions upon antigen engagement. The earliest applications of CAR-T therapy targeted CD19, a B-cell surface antigen, leading to remarkable clinical responses in relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma. FDA approvals of tisagenlecleucel and axicabtagene ciloleucel validated this modality as a therapeutic breakthrough in hematologic malignancies [24]. These therapies achieve complete remission rates exceeding 80% in certain patient cohorts, demonstrating the capacity of engineered immunity to overcome conventional therapeutic resistance.

However, the translation of CAR-T cell therapy to solid tumors presents formidable challenges due to factors such as tumor heterogeneity, antigen loss, immunosuppressive microenvironments, and physical barriers that restrict T-cell trafficking. Strategies to address these limitations include the design of CARs targeting multiple antigens (dual or tandem CARs), incorporation of "armored" CAR-T cells secreting cytokines such as IL-12 or IL-15, and integration of safety switches like inducible caspase-9 systems to mitigate cytokine release syndrome (CRS) and neurotoxicity [25]. Recent innovations focus on alternative effector populations such as CAR-Natural Killer (CAR-NK) cells, which exhibit reduced risk of graft-versus-host disease (GVHD) and improved safety profiles. Additionally, allogeneic "off-the-shelf" CAR-T products derived from healthy donors are under active investigation to reduce cost and manufacturing time, leveraging gene-editing platforms such as CRISPR/Cas9 and TALEN to eliminate endogenous TCR expression and prevent alloreactivity [26].

Emerging generations of CAR-T cells are designed with synthetic gene circuits and logic gates that enable context-dependent activation, minimizing off-tumor toxicity. Integration with artificial intelligence-driven modeling is facilitating the prediction of antigen escape patterns, optimization of CAR design, and dynamic adjustment of dosing regimens [27]. Collectively,

CAR-T cell therapy embodies a convergence of synthetic biology, precision medicine, and immune engineering heralding a new era of adaptive immune reprogramming for both hematologic and solid malignancies.

1.5 Neoantigen-Based and Personalized Cancer Vaccines

Neoantigen-based cancer vaccines epitomize the principles of precision immunotherapy by targeting tumor-specific antigens generated through somatic mutations. These neoantigens, absent in normal tissues, are presented by MHC molecules and recognized as "non-self" by cytotoxic T lymphocytes (CTLs), eliciting highly specific immune responses without inducing autoimmunity [28]. The advent of next-generation sequencing (NGS) and bioinformatics pipelines has enabled the rapid identification of neoantigens from individual tumor genomes, revolutionizing vaccine design through personalized immunogenomics. Mechanistically, cancer vaccines aim to enhance antigen presentation and T-cell priming within lymphoid organs. Platforms include peptide-based, mRNA, dendritic cell (DC)-based, and viral vector-based formulations. Among these, mRNA vaccines have gained significant traction due to their rapid development timeline, scalability, and favorable safety profiles, as demonstrated by the success of COVID-19 mRNA vaccine technology. Personalized mRNA vaccines such as mRNA-4157 (Moderna) and BNT122 (BioNTech) have entered phase II and III trials for melanoma and pancreatic cancer, respectively, showing encouraging immunogenicity and durable responses when combined with checkpoint inhibitors [29].

DC-based vaccines such as sipuleucel-T, approved for metastatic castration-resistant prostate cancer, have paved the way for antigen-loaded DC platforms utilizing autologous or allogeneic cells. These vaccines function by enhancing antigen cross-presentation and priming naïve T cells against tumor epitopes. Moreover, adjuvant systems incorporating Toll-like receptor (TLR) agonists, nanoparticles, or liposomal formulations further amplify immune activation and sustain memory responses [30]. Neoantigen prediction algorithms using deep learning models, including Net MHC pan and Deep Neo, have improved the accuracy of epitope selection by integrating peptide-binding affinity, expression levels, and proteasomal processing data. Coupled with single-cell sequencing and spatial transcriptomics, these approaches allow comprehensive mapping of tumor heterogeneity and immune infiltration patterns [31].

Clinical translation, however, remains constrained by tumor evolution, immune escape, and logistical challenges in individualized vaccine manufacturing. Nonetheless, the combination of personalized vaccines with ICIs, oncolytic viruses, or adoptive T-cell therapies is emerging as a powerful strategy to convert immunologically "cold" tumors into "hot" responsive phenotypes. Future directions include off-the-shelf neoantigen libraries, AI-optimized epitope discovery, and integration of nanocarrier-based delivery to improve stability and targeted immune engagement [32].

1.6 Tumor Microenvironment and Mechanisms of Immune Evasion

The tumor microenvironment (TME) constitutes a complex and dynamic ecosystem comprising cancer cells, stromal fibroblasts, immune infiltrates, extracellular matrix components, and soluble mediators. It plays a decisive role in dictating the success or failure of immunotherapy by orchestrating mechanisms of immune suppression and metabolic reprogramming [33]. One of the hallmark features of the TME is the infiltration of immunosuppressive cell populations, including Tregs, MDSCs, and TAMs, which secrete cytokines such as TGF-β, IL-10, and VEGF that impair T-cell effector functions. Additionally, the upregulation of indoleamine 2,3-dioxygenase (IDO) and adenosine-producing enzymes CD39/CD73 results in local depletion of tryptophan and accumulation of immunosuppressive metabolites, further attenuating immune activation [34].

Metabolic competition within the TME exacerbates immune dysfunction, as cancer cells preferentially consume glucose and oxygen through aerobic glycolysis (the Warburg effect), depriving effector T cells of essential nutrients. Hypoxia-induced stabilization of HIF-1α promotes the expression of PD-L1 and other inhibitory molecules, reinforcing immune escape [35]. Targeting the TME has therefore become a central

focus of combination immunotherapy. Strategies include reprogramming TAMs from an M2 (pro-tumoral) to M1 (anti-tumoral) phenotype using CSF-1R inhibitors, depleting MDSCs via phosphodiesterase inhibitors or chemotherapy, and neutralizing TGF-β signaling to restore T-cell infiltration. Agents like bintrafusp alfa, a bifunctional fusion protein targeting PD-L1 and TGF-β, exemplify the translational success of such dual-modality therapies [36].

Nanomedicine is playing an increasingly significant role in modulating the TME by enabling targeted delivery of immunostimulatory agents, cytokines, or checkpoint inhibitors directly into tumor sites. For example, lipid-based nanoparticles encapsulating siRNAs against IDO or PD-L1 have shown promising preclinical outcomes in reactivating local immunity and synergizing with systemic ICIs [37]. Comprehensive understanding of TME dynamics through single-cell proteomics, metabolomics, and imaging mass cytometry has unveiled spatial and temporal heterogeneity that can inform therapy design. Ultimately, reengineering the TME from an immune-suppressive to an immune-permissive state is fundamental to achieving durable and universal responses to immunotherapy across diverse cancer types [38].

1.7 Next-Generation Bispecific and Trispecific Antibody Constructs

The emergence of bispecific and trispecific antibody constructs marks a pivotal advancement in the field of immune-oncology, bridging the gap between conventional monoclonal antibodies and complex cellular therapies. These engineered molecules simultaneously engage multiple antigens or receptors, thereby enhancing specificity, potency, and immune synapse formation between effector and target cells [39]. Bispecific T-cell engagers (BiTEs) are among the most clinically advanced formats, exemplified by blinatumomab, which simultaneously binds CD3 on T cells and CD19 on B-cell malignancies, effectively redirecting cytotoxic T cells toward tumor eradication. Similar constructs targeting BCMA (teclistamab), CD20 (mosunetuzumab), and GPRC5D (talquetamab) have demonstrated substantial clinical efficacy in multiple myeloma and lymphomas [40].

Next-generation designs incorporate trispecific antibodies capable of binding two tumor antigens and one immune receptor, broadening the scope of antigen coverage and reducing the risk of immune escape. Additionally, Fc engineering and half-life extension strategies enhance pharmacokinetics and reduce dosing frequency. These multifunctional constructs can simultaneously block immune checkpoints (e.g., PD-1, LAG-3) and stimulate co-stimulatory receptors (e.g., CD28, 4-1BB), generating potent antitumor synergy [41]. Recent preclinical developments include “checkpoint engager” antibodies that selectively target inhibitory receptors within the TME while sparing systemic tissues, reducing irAEs. Moreover, bispecific formats incorporating cytokine payloads such as IL-15 or IL-21 are under evaluation for enhancing T-cell persistence and memory formation [42].

Integration with nanotechnology has further refined the pharmacodynamics of these constructs, allowing precise spatial control of antibody localization and controlled release. Computational protein design and AI-guided modeling are now central to optimizing structural stability and receptor affinity, expediting discovery pipelines [43]. In summary, bispecific and trispecific antibody platforms are redefining immunotherapeutic design principles, providing a versatile interface between biologics, cellular therapy, and molecular engineering. Their modularity, adaptability, and superior efficacy profiles position them as indispensable tools in the future of cancer immunotherapy.

1.8 Adverse Immune-Related Events: Mechanisms and Management

The success of immune checkpoint inhibitors (ICIs) and other immunotherapeutic modalities is accompanied by the emergence of immune-related adverse events (irAEs), which represent a major clinical challenge in oncologic immunotherapy. Unlike conventional chemotherapy-induced toxicities, irAEs are driven by aberrant immune activation and systemic inflammation resulting from the loss of self-tolerance mechanisms. These adverse effects can involve virtually any organ system, with the skin, gastrointestinal tract, liver, endocrine glands, and lungs being most commonly affected [44]. Mechanistically, irAEs arise when

checkpoint blockade disrupts the balance between immune activation and tolerance. CTLA-4 inhibition induces widespread T-cell activation at the priming stage, increasing the frequency of autoreactive clones, whereas PD-1/PD-L1 blockade primarily affects peripheral tolerance mechanisms, enhancing cytotoxic responses that can damage normal tissues expressing shared antigens [45]. Molecular analyses have revealed that irAEs are associated with expanded T-cell receptor (TCR) diversity, cross-reactivity between tumor and self-antigens, and the release of inflammatory cytokines such as IL-6, TNF-α, and IFN-γ [46].

Clinically, irAEs are graded from mild (Grade 1) to life-threatening (Grade 4) based on the Common Terminology Criteria for Adverse Events (CTCAE). Dermatologic reactions such as maculopapular rash or vitiligo are often early indicators, while severe complications like colitis, hepatitis, pneumonitis, and myocarditis may develop later in the treatment course. Endocrinopathies such as hypophysitis, thyroiditis, and adrenal insufficiency are frequently irreversible, necessitating lifelong hormone replacement [47]. Management strategies focus on prompt recognition, grading, and initiation of immunosuppressive therapy. Corticosteroids remain the mainstay of treatment, with additional immunomodulatory agents such as infliximab (anti-TNF), mycophenolate mofetil, or vedolizumab used for steroid-refractory cases. Importantly, evidence suggests that appropriate immunosuppression does not significantly diminish the anticancer efficacy of ICIs if administered judiciously [48].

Emerging research has shifted toward predictive and preventive measures. Biomarkers such as baseline autoantibody profiles, cytokine signatures, gut microbiome composition, and HLA genotypes have shown potential in identifying patients at higher risk for irAEs. Furthermore, AI-driven algorithms integrating longitudinal laboratory data and clinical imaging are being developed for early detection and dynamic risk assessment [49]. With the expanding repertoire of immunotherapies including CAR-T cells, bispecific antibodies, and combination regimens the spectrum of immune-mediated toxicities continues to evolve. Thus, establishing standardized management protocols, multidisciplinary monitoring, and pharmacovigilance systems will be essential to balance therapeutic efficacy with safety in the era of immune-oncology [50].

1.9 Clinical Approvals and Ongoing Trials (2019–2025)

Between 2019 and 2025, the landscape of clinical oncology has been transformed by the accelerated approval of immunotherapeutic agents targeting novel checkpoints and pathways. These advancements have not only expanded indications for established agents such as pembrolizumab and nivolumab but also introduced next-generation antibodies, cellular therapies, and combination regimens that redefine the boundaries of cancer treatment [51]. In the checkpoint inhibitor domain, FDA approvals during this period have included dostarlimab (anti–PD-1) for mismatch repair-deficient endometrial cancer, cemiplimab for cutaneous squamous cell carcinoma, and relatlimab (anti–LAG-3) in combination with nivolumab for melanoma. The dual LAG-3 and PD-1 blockade exemplifies the shift toward multi-target immunotherapy designed to overcome adaptive resistance mechanisms [52]. Similarly, toripalimab and sintilimab, developed in Asia, have achieved global recognition through pivotal trials demonstrating efficacy across nasopharyngeal carcinoma and hepatocellular carcinoma, highlighting the globalization of immuno-oncology [53].

CAR-T cell therapies have expanded beyond hematologic malignancies. Brexucabtagene autoleucel and lisocabtagene maraleucel received approvals for mantle cell lymphoma and large B-cell lymphoma, respectively. More recently, idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti), targeting BCMA, have revolutionized the treatment of multiple myeloma. Ongoing phase I/II studies are evaluating solid tumor-directed CAR constructs against antigens such as mesothelin, HER2, and GD2, supported by advances in tumor microenvironment modulation [54]. Neoantigen vaccine trials, such as the KEYNOTE-942 (mRNA-4157) study, have demonstrated significant improvements in recurrence-free survival when combined with pembrolizumab for melanoma, validating the clinical utility of personalized immunogens. Furthermore, bispecific antibody approvals including teclistamab and

mosunetuzumab have established a new therapeutic class capable of bridging immune effector and tumor cells without ex vivo manipulation [55].

Table 1 provides a summary of key immunotherapy approvals between 2019 and 2025, highlighting the therapeutic class, primary indication, and notable outcomes.

The future of immunotherapy lies at the intersection of computational intelligence, systems biology, and nanotechnology. As the complexity of cancer–immune interactions becomes increasingly apparent, a holistic, data-driven approach is essential to enhance treatment precision, minimize toxicity, and predict therapeutic outcomes.

Table 1. Selected FDA-Approved and Late-Stage Immunotherapies (2019–2025)

Agent (Class)	Target(s)	Cancer Type(s)	Approval/Trial Phase	Key Outcomes
Dostarlimab	PD-1	Endometrial carcinoma (MMR-deficient)	FDA Approved (2021)	ORR 42%, durable responses
Relatlimab + Nivolumab	LAG-3 + PD-1	Melanoma	FDA Approved (2022)	PFS 10.1 mo vs 4.6 mo (nivolumab alone)
Idecabtagene vicleucel	BCMA (CAR-T)	Multiple myeloma	FDA Approved (2021)	ORR 73%, CR 33%
Teclistamab	BCMA × CD3 (BiTE)	Multiple myeloma	FDA Approved (2022)	ORR 63%, median DoR 18.4 mo
mRNA-4157 + Pembrolizumab	Neoantigen vaccine + PD-1	Melanoma	Phase III (KEYNOTE-942)	44% reduction in recurrence risk
Bintrafusp alfa	PD-L1 + TGF-β	Solid tumors	Phase II (Ongoing)	Dual blockade shows synergistic T-cell activation

These milestones illustrate a clear trend toward combination and personalized immunotherapy. The regulatory landscape now emphasizes adaptive trial designs, biomarker-guided enrollment, and global harmonization of clinical endpoints. The cumulative data indicate that between 2019 and 2025, immunotherapy approvals have accounted for nearly 40% of all oncology drug authorizations a testament to the field's maturity and clinical relevance [56].



Figure 1. Integrated Landscape of Modern Cancer Immunotherapy: Mechanisms, Modalities, and Future Convergence with AI and Nanomedicine

1.10 Future Perspectives: Integrating Immunotherapy with AI, Nanomedicine, and Omics Data

Artificial intelligence (AI), particularly deep learning and graph neural networks, is revolutionizing immuno-oncology by enabling large-scale integration of clinical, genomic, transcriptomic, and imaging data for patient stratification and drug response prediction [57]. AI-assisted biomarker discovery utilizes machine learning algorithms to correlate high-dimensional omics datasets with therapeutic outcomes, identifying signatures predictive of checkpoint inhibitor responsiveness. Radiomics and digital pathology further complement these efforts by quantifying tumor-infiltrating lymphocyte density, PD-L1 expression patterns, and spatial immune architecture from imaging data, allowing non-invasive, real-time monitoring of treatment dynamics [58].

Nanomedicine contributes another transformative dimension by enhancing the pharmacokinetics, biodistribution, and safety of

immunotherapeutic agents. Engineered nanoparticles, liposomes, and polymeric micelles facilitate targeted delivery of antibodies, cytokines, or siRNAs within the tumor microenvironment, improving therapeutic index while reducing systemic exposure. Smart nanocarriers capable of responding to pH, redox, or enzymatic triggers allow controlled drug release in situ, optimizing immune activation kinetics. Furthermore, integration with multi-omics platforms including genomics, proteomics, metabolomics, and single-cell transcriptomics enables a comprehensive understanding of tumor evolution and immune adaptation. This multi-dimensional framework supports the design of adaptive immunotherapy regimens that evolve in tandem with tumor dynamics, a concept referred to as "immuno-evolutionary precision medicine." The combination of AI-based predictive modeling with nanocarrier-enabled targeted delivery forms the foundation of next-generation digital immunotherapy ecosystems.

The convergence of these disciplines also raises novel regulatory, ethical, and economic challenges. Ensuring algorithmic transparency, equitable data representation, and cross-border data sharing will be crucial for global implementation. Moreover, the development of AI-assisted clinical decision support systems (CDSS) will transform oncologists from passive prescribers to active orchestrators of personalized immune modulation. Ultimately, the integration of immunotherapy with AI and nanomedicine heralds a transition from reactive to proactive cancer care where computational foresight, molecular precision, and immune reprogramming collectively define the blueprint for the next decade of oncology innovation.

Conclusion

Immunotherapy has irrevocably transformed the landscape of cancer treatment by shifting the paradigm from tumor-targeted cytotoxicity to immune system reactivation and modulation. The advancements from 2019 to 2025 have witnessed the maturation of checkpoint blockade, the diversification of CAR-T and neoantigen vaccine platforms, and the emergence of next-generation antibody architectures. Despite challenges posed by resistance mechanisms, immune-related toxicities, and economic barriers, ongoing innovation continues to refine efficacy, safety, and accessibility. The fusion of immunotherapy with AI, multi-omics analytics, and nanomedicine represents the frontier of precision oncology one that promises predictive, personalized, and adaptive immune interventions. As the global immuno-oncology ecosystem evolves, multidisciplinary collaboration between clinicians, data scientists, bioengineers, and regulatory bodies will be pivotal in actualizing the full therapeutic potential of the immune system against cancer.

References

1. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. *Nature*. 2011;480(7378):480–489.
2. Sharma P, Allison JP. The future of immune checkpoint therapy. *Science*. 2015;348(6230):56–61.
3. Chen DS, Mellman I. Elements of cancer immunity and the cancer–immune set point. *Nature*. 2017;541(7637):321–330.
4. Tang J, Yu JX, Hubbard-Lucey VM, Neftelinov ST, Hodge JP, Lin Y. The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. *Nat Rev Drug Discov*. 2018;17(12):854–855.
5. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. *Science*. 2018;359(6382):1350–1355.
6. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition. *Am J Clin Oncol*. 2016;39(1):98–106.
7. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. *J Exp Med*. 1995;182(2):459–465.
8. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. *Immunol Rev*. 2010;236(1):219–242.
9. Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: Breakthroughs or backups. *Nat Immunol*. 2019;20(11):1425–1434.
10. Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-

mediated inhibition. *Science*. 2017;355(6332):1428–1433.

11. Kim JH, Kim TW. Immune checkpoint inhibitors for the treatment of cancer: A clinical update. *Exp Mol Med*. 2020;52(3):367–379.
12. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non–small-cell lung cancer. *N Engl J Med*. 2016;375(19):1823–1833.
13. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. *N Engl J Med*. 2012;366(26):2443–2454.
14. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1–positive, advanced NSCLC. *Lancet*. 2016;387(10027):1540–1550.
15. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science*. 2017;357(6349):409–413.
16. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal-cell carcinoma. *N Engl J Med*. 2018;378(14):1277–1290.
17. Doi T, Fujiwara Y, Koyama T, et al. Phase I study of bifunctional anti–PD-L1/TGF-βRII agent bintrafusp alfa in advanced solid tumors. *Clin Cancer Res*. 2020;26(17):4668–4677.
18. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-term outcomes with nivolumab plus ipilimumab in advanced melanoma. *J Clin Oncol*. 2022;40(2):127–137.
19. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. *N Engl J Med*. 2018;378(2):158–168.
20. June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. *Science*. 2018;359(6382):1361–1365.
21. Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. *Science*. 2018;359(6382):1355–1360.
22. Binnewies M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. *Nat Med*. 2018;24(5):541–550.
23. Labrijn AF, Janmaat ML, Reichert JM, Parren P. Bispecific antibodies: A mechanistic review of the pipeline. *Nat Rev Drug Discov*. 2019;18(8):585–608.
24. Luke JJ, Barrio A, Larkin J, et al. The next generation of immune checkpoint therapy in oncology. *Nat Med*. 2022;28(12):2450–2464.
25. Reardon DA, Brandes AA, Omuro A, et al. Immunotherapy for glioblastoma: The next frontier. *Nat Rev Clin Oncol*. 2023;20(2):109–124.
26. Kwon ED, Drake CG, Scher HI, et al. Future directions in immuno-oncology: A global perspective. *Nat Rev Clin Oncol*. 2023;20(4):251–269.
27. Li AM, Ngai JC, Chan SK, et al. Artificial intelligence in oncology: Advancing clinical decision-making with machine learning and deep neural networks. *Nat Rev Clin Oncol*. 2023;20(9):576–589.
28. Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. *Nature*. 2017;547(7662):217–221.
29. Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. *Nature*. 2017;547(7662):222–226.
30. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. *Nat Rev Cancer*. 2012;12(4):265–277.
31. Wells DK, van Buuren MM, Dang KK, et al. Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. *Cell*. 2020;183(3):818–834.
32. Kreiter S, Vormehr M, van de Roemer N, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. *Nature*. 2015;520(7549):692–696.

33. Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. *Cancer Res*. 2019;79(18):4557–4566.
34. Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. *Immunity*. 2020;52(1):17–35.
35. Leone RD, Powell JD. Metabolism of immune cells in cancer. *Nat Rev Cancer*. 2020;20(9):516–531.
36. Lan Y, Zhang D, Xu C, et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β. *Sci Transl Med*. 2018;10(424):eaam5373.
37. Ni K, Luo T, Lan G, et al. A nanoscale metal–organic framework to mediate photodynamic therapy and deliver checkpoint blockade antibodies. *Nat Commun*. 2018;9(1):1–10.
38. Guo X, Zhang Y, Zheng L, et al. Global characterization of T cells in non–small cell lung cancer by single-cell sequencing. *Nat Med*. 2018;24(7):978–985.
39. Labrijn AF, Janmaat ML, Reichert JM, Parren P. Bispecific antibodies: A mechanistic review of the pipeline. *Nat Rev Drug Discov*. 2019;18(8):585–608.
40. Topp MS, Duell J, Zugmaier G, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. *Blood*. 2020;135(22):1784–1793.
41. Li J, Stagg NJ, Johnston J, et al. Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5/CD3 bispecific antibody. *Clin Cancer Res*. 2017;23(6):1506–1518.
42. Wu L, Seung E, Xu L, et al. Trispecific antibodies enhance the breadth of tumor antigen targeting and overcome resistance mechanisms. *Nat Biotechnol*. 2022;40(6):935–947.
43. Xu Y, Roach W, Sun T, et al. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: A FACS-based, high-throughput selection strategy. *mAbs*. 2013;5(5):858–873.
44. Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance. *Nat Rev Clin Oncol*. 2019;16(9):563–580.
45. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. *N Engl J Med*. 2018;378(2):158–168.
46. Das R, Bar N, Ferreira M, et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. *J Clin Invest*. 2018;128(2):715–720.
47. Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. *JAMA Oncol*. 2018;4(12):1721–1728.
48. Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non–small-cell lung cancer. *J Clin Oncol*. 2018;36(28):2872–2878.
49. Khan S, Gerber DE. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review. *Semin Cancer Biol*. 2020;64:93–101.
50. Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: Long-term implications of toxicity. *Nat Rev Clin Oncol*. 2022;19(4):254–267.
51. Tang J, Pearce L, O'Donnell-Tormey J, Hubbard-Lucey VM. Trends in the global immuno-oncology landscape. *Nat Rev Drug Discov*. 2018;17(11):783–784.
52. Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. *N Engl J Med*. 2022;386(1):24–34.
53. Wang J, Xu B, Sun T, et al. Toripalimab, an anti-PD-1 antibody, in patients with advanced solid tumors: Results of a phase I study. *Oncoimmunology*. 2019;8(7):e1529799.
54. Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. *N Engl J Med*. 2021;384(8):705–716.

55. Sahin U, Oehm P, Derhovanessian E, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. *Nature*. 2020;585(7823):107–112.
56. Zhao X, Subramanian S. Oncologic drug approvals in the era of immune checkpoint inhibitors: 2019–2025 trends. *Nat Rev Drug Discov*. 2024;23(3):181–195.
57. Esteva A, Topol EJ. Can deep learning revolutionize cancer immunotherapy? *Nat Med*. 2019;25(10):1457–1459.
58. Kather JN, Calderaro J. Artificial intelligence in oncology: From bench to bedside. *Nat Rev Clin Oncol*. 2020;17(10):683–692.